Please assess the completion status of the following clinical trial:

Trial Title: Topiramate as a Treatment for Levodopa-Induced Dyskinesia in Parkinson's Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* UK PD Society Brain Bank criteria for the diagnosis of idiopathic PD.~* Patients with stable levodopa-induced dyskinesias present greater than 25% of the day (Unified Parkinson's Disease Rating Scale (UPDRS), item 32, rating \> 2) and be moderately to completely disabling (UPDRS item 33, rating \> 2).~* All anti-parkinsonian medications must be stable for at least one month prior to study enrollment.~Exclusion Criteria:~* Include prior surgery for PD~* Hoehn and Yahr score of 5 when off~* History of nephrolithiasis~* Renal impairment~* Liver disease~* Pregnancy~* Premenopausal females and males not using adequate contraception~* Cognitive impairment (Mini Mental State Exam score less than 24)~* History of glaucoma or seizures~* Use of other antiepileptic drugs~* Amantadine~* Carbonic anhydrase inhibitors~* Digoxin~* Metformin~* Or illicit drugs

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).